Texas Roadhouse earnings missed by $0.05, revenue topped estimates
LONDON - Haleon PLC (LSE/NYSE: HLN), a global consumer health company, announced a change to its Board of Directors today. Following the decline of Pfizer Inc. (NYSE:PFE)’s shareholding in Haleon to below 10%, Bryan Supran, who served as a Non-Executive Director representing Pfizer, resigned from his position on the Board effective immediately.
The departure of Supran is in accordance with the terms outlined in the Pfizer Relationship Agreement with Haleon. This agreement had provisions for board representation contingent on Pfizer’s ownership percentage in Haleon.
Sir Dave Lewis (JO:LEWJ), the Chair of Haleon, expressed gratitude for Supran’s service, stating, "On behalf of the Board, I would like to thank Bryan for his contributions to the Board’s discussions and for being part of the Haleon journey from the initial joint-venture in 2019 through demerger to today. We wish him all the very best for the future."
Haleon, known for its portfolio of health products including well-known brands such as Advil, Sensodyne, and Centrum, has not disclosed any additional details regarding the Board change under UK Listing Rule 6.4.6R.
This corporate update is based on a press release statement from Haleon and provides shareholders and the public with the latest developments in the company’s governance structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.